NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Elliott Associates may sue AbbVie over scuttled deal

Published 05/11/2014, 19:05
© Reuters A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange
SHP
-
ABBV
-

By Svea Herbst-Bayliss

BOSTON (Reuters) - Hedge fund Elliott Associates may take legal action against pharmaceuticals company AbbVie Inc (N:ABBV) for scuttling a merger deal with Shire Plc (L:SHP).

Elliott said in a quarterly letter to investors that it was disappointed when AbbVie's board withdrew its support for the deal in October after executives had signalled strong interest in late September.

The $25.4 billion (15.89 billion pound) New York-based hedge fund founded by Paul Singer holds 7.85 million shares of Shire, according to a regulatory filing made on Oct. 15.

"We are exploring our options with respect to this matter, including whether to assert claims against AbbVie for making false and misleading statements about the transaction," the fund wrote in the letter, which was seen by Reuters.

Elliott Associates said it made money on its Shire position in the third quarter, but suffered a loss in the fourth quarter when the share price tumbled on news the deal would collapse.

The AbbVie-Shire deal was a so-called inversion transaction in which the acquiring company moves its headquarters to its target's home base to take advantage of lower tax rates.

The U.S. government threw cold water on these deals in September when it issued rules limiting the tax benefits.

Elliott said these changes should not have influenced the prospects for the AbbVie Shire tie-up.

"While the Treasury regulations reduced the attractiveness of the transaction to AbbVie, it would have been significantly accretive to AbbVie while preserving the aforementioned strategic benefits," the letter said.

An Elliott spokesman declined to elaborate further. An AbbVie official did not immediately respond to a request for comment.

Elliott is closely watched in the hedge fund industry, both for its strong returns and its willingness to wage lawsuits.

© Reuters. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange

The fund gained 7.6 percent for the year through the end of September and rose 2.9 percent during the third quarter. It did not say how much the bet on Shire helped during the third quarter or hurt more recently.

(Reporting by Svea Herbst-Bayliss; Editing by Richard Valdmanis, Chizu Nomiyama and Andre Grenon)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.